Gainers
- Rockwell Medical RMTI stock rose 9.2% to $0.4 during Monday's after-market session. The company's market cap stands at $37.5 million.
- Biodesix BDSX shares moved upwards by 8.55% to $1.46. The market value of their outstanding shares is at $56.1 million.
- Regulus Therapeutics RGLS stock moved upwards by 6.72% to $0.25. The company's market cap stands at $37.0 million.
- Alaunos Therapeutics TCRT stock increased by 5.77% to $0.43. The market value of their outstanding shares is at $93.7 million.
- ARCA biopharma ABIO stock moved upwards by 5.6% to $2.45. The company's market cap stands at $35.3 million.
- Surgalign Holdings SRGA stock moved upwards by 5.53% to $0.25. Surgalign Holdings's trading volume hit 63.2K shares by close, accounting for 1.7% of its average volume over the last 100 days. The company's market cap stands at $49.6 million.
Losers
- ACADIA Pharmaceuticals ACAD stock declined by 7.1% to $20.81 during Monday's after-market session. Trading volume for this security closed at 73.6K, accounting for 4.9% of its average full-day volume over the last 100 days. The company's market cap stands at $3.3 billion.
- HTG Molecular Diagnostics HTGM shares decreased by 6.49% to $1.01. The company's market cap stands at $10.9 million.
- TherapeuticsMD TXMD shares fell 5.0% to $0.27. Trading volume for this security closed at 644.1K, accounting for 9.4% of its average full-day volume over the last 100 days. The market value of their outstanding shares is at $117.0 million.
- Zentalis Pharmaceuticals ZNTL shares fell 4.99% to $23.26. The market value of their outstanding shares is at $1.0 billion.
- Axonics AXNX shares fell 4.99% to $57.92. Axonics's trading volume hit 69.7K shares by close, accounting for 15.4% of its average volume over the last 100 days. The company's market cap stands at $2.7 billion.
- Homology Medicines FIXX stock fell 4.88% to $1.95. The company's market cap stands at $111.9 million. See Also: www.benzinga.com/money/best-healthcare-stocks/
This article was generated by Benzinga's automated content engine and reviewed by an editor.
© 2025 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...